Study of Low Molecular Weight Heparins (DANHEP)

Herlev Hospital

Status and phase

Enrolling

Phase 4

Conditions

Venous Thromboembolism

Treatment

Prophylaxis

Anticoagulant

Treatments

Drug: Dalteparin Prefilled Syringe

Drug: Tinzaparin profiled syringe

Study type

Interventional

Funder types

Other

Identifiers

NCT06020560

DANHEP

Details and patient eligibility

About

DANHEP is a cluster randomized study of two different low molecular weight heparins. Parenteral anticoagulants are used in a variety of settings, including treatment and prevention of venous thromboembolism in cancer patients, medical patients, and surgical patients, along with the use as adjuvant therapy for coronary syndromes. The most frequently used parenteral anticoagulants in Denmark, include the two different low molecular weight heparins; dalteparin and tinzaparin. The two drugs are considered equally efficient and safe regarding treatment and prevention of thrombosis and risk of bleeding. Importantly, there is a lack of evidence regarding whether these drugs are in fact comparable. The aim of this study is therefore to investigate the comparative safety and efficacy of the two different low molecular weight heparins (dalteparin and tinzaparin using cluster randomization in patients with an indication for low molecular weight heparins.

Enrollment

65,000 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

All patients with indication for low molecular weight heparin

Exclusion criteria

Patients under the age of 18
Patients who are incapable of understanding the written material received
Patients who after being informed in writing chooses not to participate
Patients with contraindications for low molecular weight heparins as described in the SmPC